Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Liabilities and Shareholders Equity: 2010-2025

Historic Liabilities and Shareholders Equity for Ironwood Pharmaceuticals (IRWD) over the last 15 years, with Sep 2025 value amounting to $396.1 million.

  • Ironwood Pharmaceuticals' Liabilities and Shareholders Equity rose 1.68% to $396.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year decrease of 16.40%. This contributed to the annual value of $350.9 million for FY2024, which is 25.51% down from last year.
  • Per Ironwood Pharmaceuticals' latest filing, its Liabilities and Shareholders Equity stood at $396.1 million for Q3 2025, which was up 15.49% from $342.9 million recorded in Q2 2025.
  • Ironwood Pharmaceuticals' 5-year Liabilities and Shareholders Equity high stood at $1.2 billion for Q1 2023, and its period low was $327.2 million during Q1 2025.
  • In the last 3 years, Ironwood Pharmaceuticals' Liabilities and Shareholders Equity had a median value of $396.1 million in 2025 and averaged $490.4 million.
  • As far as peak fluctuations go, Ironwood Pharmaceuticals' Liabilities and Shareholders Equity spiked by 127.09% in 2021, and later tumbled by 62.02% in 2024.
  • Quarterly analysis of 5 years shows Ironwood Pharmaceuticals' Liabilities and Shareholders Equity stood at $1.1 billion in 2021, then dropped by 2.34% to $1.1 billion in 2022, then crashed by 57.20% to $471.1 million in 2023, then decreased by 25.51% to $350.9 million in 2024, then grew by 1.68% to $396.1 million in 2025.
  • Its last three reported values are $396.1 million in Q3 2025, $342.9 million for Q2 2025, and $327.2 million during Q1 2025.